Emerging role of amyloid-β test using CSF biomarker

Takeshi Ikeuchi

Department of Molecular Genetics, Brain Research Institute, Niigata University

The development of cerebrospinal fluid （CSF） biomarkers enabled the estimation of neuropathological changes with high accuracy in patients with Alzheimer's disease （AD）.　Lecanemab, an anti-amyloid-β （Aβ） antibody, has received regulatory approval and its clinical use was already launched in Japan.　To select patients to be treated with Lecanemab, amyloid-β test is required to confirm the Aβ accumulation in the brain by CSF or amyloid PET test.　CSF Aβ42 and 40 measurements have been approved as in vitro diagnostic and covered by public insurance as amyloid-β test for Lecanemab.　New healthcare system that can provide timely and accessible amyloid-β test and subsequent equitable anti-Aβ antibody therapy need to be established on a nationwide basis.

Address correspondence to Dr. Takeshi Ikeuchi, Department of Molecular Genetics, Brain Research Institute, Niigata University（1-757 Asahimachi, Niigata 951-8585, Japan）